Abstract
Cystatin C (cys-C) is a small protein molecule (120 amino acid peptide chain, approximately 13kDa) produced by virtually all nucleated cells in the human body. It belongs to the family of papain-like cysteine proteases and its main biological role is the extracellular inhibition of cathepsins. It’s near constant production rate, the fact that it is freely filtered from the glomerular membrane and then completely reabsorbed without being secreted from the proximal tubular cells, made it an almost perfect candidate for estimating renal function. The strong correlation between chronic kidney disease (CKD) and cardiovascular disease (CVD) along with the growing understanding of the role of cysteinyl cathepsins in the pathophysiology of CVD inspired researchers to explore the potential association of cys-C with CVD. Throughout the spectrum of CVD (peripheral arterial disease, stroke, abdominal aortic aneurysm, heart failure, coronary artery disease) adverse outcomes and risk stratification have been associated with high plasma levels of cys-C. The exact mechanisms behind the observed correlations have not been comprehensively clarified. Plausible links between high cys-C levels and poor cardiovascular outcome could be impaired renal function, atherogenesis and inflammatory mediators, remodeling of myocardial tissue and others (genetic factors, aging and social habits). The scope of the present article is to systematically review the current knowledge about cys-C biochemistry, metabolism, methods of detection and quantification and pathophysiological associations with different aspects of CVD.
Keywords: Biomarker, cardiovascular disease, chronic kidney disease, coronary artery disease, cystatin-C, cysteinyl cathepsins, heart failure, peripheral arterial disease
Current Topics in Medicinal Chemistry
Title:Cystatin C: An Emerging Biomarker in Cardiovascular Disease
Volume: 13 Issue: 2
Author(s): Christos Angelidis, Spyridon Deftereos, Georgios Giannopoulos, Nikolaos Anatoliotakis, Georgios Bouras, Georgios Hatzis, Vasiliki Panagopoulou, Vlasios Pyrgakis and Michael W. Cleman
Affiliation:
Keywords: Biomarker, cardiovascular disease, chronic kidney disease, coronary artery disease, cystatin-C, cysteinyl cathepsins, heart failure, peripheral arterial disease
Abstract: Cystatin C (cys-C) is a small protein molecule (120 amino acid peptide chain, approximately 13kDa) produced by virtually all nucleated cells in the human body. It belongs to the family of papain-like cysteine proteases and its main biological role is the extracellular inhibition of cathepsins. It’s near constant production rate, the fact that it is freely filtered from the glomerular membrane and then completely reabsorbed without being secreted from the proximal tubular cells, made it an almost perfect candidate for estimating renal function. The strong correlation between chronic kidney disease (CKD) and cardiovascular disease (CVD) along with the growing understanding of the role of cysteinyl cathepsins in the pathophysiology of CVD inspired researchers to explore the potential association of cys-C with CVD. Throughout the spectrum of CVD (peripheral arterial disease, stroke, abdominal aortic aneurysm, heart failure, coronary artery disease) adverse outcomes and risk stratification have been associated with high plasma levels of cys-C. The exact mechanisms behind the observed correlations have not been comprehensively clarified. Plausible links between high cys-C levels and poor cardiovascular outcome could be impaired renal function, atherogenesis and inflammatory mediators, remodeling of myocardial tissue and others (genetic factors, aging and social habits). The scope of the present article is to systematically review the current knowledge about cys-C biochemistry, metabolism, methods of detection and quantification and pathophysiological associations with different aspects of CVD.
Export Options
About this article
Cite this article as:
Angelidis Christos, Deftereos Spyridon, Giannopoulos Georgios, Anatoliotakis Nikolaos, Bouras Georgios, Hatzis Georgios, Panagopoulou Vasiliki, Pyrgakis Vlasios and W. Cleman Michael, Cystatin C: An Emerging Biomarker in Cardiovascular Disease, Current Topics in Medicinal Chemistry 2013; 13 (2) . https://dx.doi.org/10.2174/1568026611313020006
DOI https://dx.doi.org/10.2174/1568026611313020006 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Chronic Kidney Disease
The scope of the special thematic issue includes but not limited to the mechanism of chronic kidney disease (CKD), the treatment of renal fibrosis and early diagnosis of CKD and so on. We also welcome manuscripts from other scientific research area with respect to internal medicine. Cell death has been ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Predicting Drug Metabolism Induction In Silico
Current Topics in Medicinal Chemistry Urotensin II: A Vascular Mediator in Health and Disease
Current Vascular Pharmacology HLA-G - From Fetal Tolerance to a Regulatory Molecule in Inflammatory Diseases
Current Immunology Reviews (Discontinued) Editorial (Thematic Issue Title: Myocardial Cell Death: Molecular Mechanisms & Drug Targets)
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Recent Patents on Proteasome Inhibitors of Natural Origin
Recent Patents on Anti-Cancer Drug Discovery The Role of microRNAs in Cardiovascular Disease
Current Medicinal Chemistry Physiological and Non-Redundant Functions of PKC Isotypes in T Lymphocytes
Current Immunology Reviews (Discontinued) New Therapeutic Aspects of Inflammatory Cardiomyopathy
Current Pharmaceutical Design Chromogranins and Inositol 1,4,5-Trisphosphate-Dependent Ca2+-Signaling in Cardiomyopathy and Heart Failure
Current Medicinal Chemistry Restoration of Chemoresistance Mechanism by Novel Drug Therapies in Breast Cancer Cell Lines
Current Drug Therapy Reactive Oxygen Species and Antioxidants in the Pathophysiology of Cardiovascular Disease: Does the Actual Knowledge Justify a Clinical Approach?
Current Vascular Pharmacology Editorial (Thematic Issue: Measuring Myocyte Oxidative Stress and Targeting Cytokines to Evaluate Inflammatory Response and Cardiac Repair after Myocardial Infarction)
Current Vascular Pharmacology Adipose Triglyceride Lipase: A New Target in the Regulation of Lipolysis by Insulin
Current Diabetes Reviews The Role of Mitochondrial Dysfunction in Heart Failure and Potential Therapeutic Targets
Current Pharmaceutical Design Generation of Human Cardiomyocytes for Cardiac Regenerative Therapies: Differentiation and Direct Reprogramming
Current Pharmaceutical Design Association Between Hypothyroidism and Takotsubo Cardiomyopathy: Analysis of Nationwide Inpatient Sample Database
Reviews on Recent Clinical Trials An In-Silico Investigation of Anti-Chagas Phytochemicals
Current Clinical Pharmacology Dynamic Crosstalk between GlcNAcylation and Phosphorylation: Roles in Signaling, Transcription and Human Disease
Current Signal Transduction Therapy Unconventional Players on the Striated Muscle Field: microRNAs, Signaling Pathways and Epigenetic Regulators
Current Stem Cell Research & Therapy